{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:20:41Z","timestamp":1794277241618,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. Anti-vascular endothelial growth factor (anti-VEGF) therapy offers an alternative to laser photocoagulation, recurrence, and retreatment, particularly in Zone II disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of studies published from 2010 to 2025 comparing anti-VEGF agents (bevacizumab, ranibizumab, aflibercept) with laser therapy in preterm infants with treatment-requiring ROP. Primary outcomes were recurrence and retreatment; secondary outcomes included time to recurrence, structural, and refractive outcomes. The risk of bias was assessed using RoB 2 and ROBINS-I tools, and the certainty of evidence was evaluated using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies with 1,784 eyes were included. Pooled recurrence (RR 1.78, 95% CI: 0.56\u20135.65) and retreatment rates (RR 1.80, 95% CI: 0.54\u20135.94) showed no statistically significant differences, with substantial heterogeneity (I\u00b2&gt;80%). Subgroup analysis showed lower recurrence in Zone I (RR 0.52) but higher recurrence in Zone II (RR 3.42) following anti-VEGF therapy. Ranibizumab was associated with higher recurrence compared to other agents. After anti-VEGF therapy, recurrence occurred variably between 7 and 50\u2009+\u2009weeks of post-treatment. GRADE assessment indicated low certainty for recurrence and retreatment, moderate for structural and refractive outcomes, and very low for neurodevelopmental safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-VEGF therapy is effective for Zone I ROP, but Zone II treatment requires careful monitoring due to higher recurrence and retreatment risk. Standardized protocols and extended follow-up are essential, and further high-quality studies are needed to optimize ROP management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00810-9","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:14:30Z","timestamp":1769786070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-VEGF versus laser therapy for retinopathy of prematurity: a systematic review and meta-analysis focusing on recurrence patterns and retreatment needs"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-8264","authenticated-orcid":false,"given":"Luksanaporn","family":"Krungkraipetch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechathorn","family":"Krungkraipetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitti","family":"Krungkraipetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"7","key":"810_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3\u2009+\u2009retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"810_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5301\/ejo.5000166","volume":"22","author":"R Autrata","year":"2012","unstructured":"Autrata R, Krejcirova I, Senkova K, Holousova M, Dolezel Z, Borek I. Intravitreal Pegaptanib combined with diode laser therapy for stage 3\u2009+\u2009retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol. 2012;22(5):687\u201394.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"810_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Xu X, et al. Comparison of intravitreal injection of Ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017;37(4):710\u20137.","journal-title":"Retina"},{"issue":"3","key":"810_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","volume":"236","author":"E Alyama\u00e7 Sukgen","year":"2016","unstructured":"Alyama\u00e7 Sukgen E, \u00c7\u00f6mez A, Ko\u00e7luk Y, Cevher S, Realized G. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison of Ranibizumab and bevacizumab. Ophthalmologica. 2016;236(3):139\u201347.","journal-title":"Ophthalmologica"},{"issue":"4","key":"810_CR5","doi-asserted-by":"publisher","first-page":"e0230678","DOI":"10.1371\/journal.pone.0230678","volume":"15","author":"M Arima","year":"2020","unstructured":"Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with retinopathy of prematurity. PLoS ONE. 2020;15(4):e0230678.","journal-title":"PLoS ONE"},{"issue":"4","key":"810_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","volume":"103","author":"Y Bai","year":"2019","unstructured":"Bai Y, Nie H, Wei S, Lu X, Ke X, Ouyang X, et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br J Ophthalmol. 2019;103(4):494\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"810_CR7","doi-asserted-by":"publisher","first-page":"e1004","DOI":"10.1111\/aos.14460","volume":"98","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Zhu X, Linghu D, Liang J. Comparison of the effectiveness of conbercept and Ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmol. 2020;98(8):e1004\u20138. https:\/\/doi.org\/10.1111\/aos.14460.","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"810_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","volume":"9","author":"M Fidler","year":"2020","unstructured":"Fidler M, Fleck BW, Stahl A, Marlow N, Chastain JE, Li J, et al. Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Technol. 2020;9(8):43.","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"810_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","volume":"6","author":"BW Fleck","year":"2022","unstructured":"Fleck BW, Reynolds JD, Zhu Q, Lepore D, Marlow N, Stahl A, et al. Time course of retinopathy of prematurity regression and reactivation after treatment with Ranibizumab or laser in the RAINBOW trial. Ophthalmol Retina. 2022;6(7):628\u201337.","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"810_CR10","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.4103\/ijo.IJO_3016_20","volume":"69","author":"AB Gangwe","year":"2021","unstructured":"Gangwe AB, Agrawal D, Gangrade AK, Parchand SM, Agrawal D, Azad RV, et al. Outcomes of early versus deferred laser after intravitreal Ranibizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2021;69(8):2171\u20136.","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"810_CR11","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M, et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016;94(6):e417\u201320. https:\/\/doi.org\/10.1111\/aos.13008.","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"810_CR12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","volume":"5","author":"N Marlow","year":"2021","unstructured":"Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, et al. 2-year outcomes of Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2021;5(10):698\u2013707.","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"810_CR13","first-page":"407","volume":"8","author":"N Marlow","year":"2024","unstructured":"Marlow N, Stahl A, Moreira A, Lepore D, Fielder A, Reynolds JD, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): 5-year outcomes of an open-label randomised controlled trial. Lancet Child Adolesc Health. 2024;8(6):407\u201316.","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"810_CR14","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153218.","journal-title":"Pediatrics"},{"issue":"2","key":"810_CR15","doi-asserted-by":"publisher","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","volume":"144","author":"G Natarajan","year":"2019","unstructured":"Natarajan G, Shankaran S, Nolen TL, Sridhar A, Kennedy KA, Hintz SR, et al. Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics. 2019;144(2):e20183537.","journal-title":"Pediatrics"},{"key":"810_CR16","doi-asserted-by":"crossref","unstructured":"Patel NA, Acaba-Berrocal LA, Hoynek S, Fan KC, Martinez-Castellanos MA, Baumal CR, et al. Practice patterns and outcomes of intravitreal anti-VEGF injection for retinopathy of prematurity: an international multicenter study. Ophthalmology. 2022;129(12):1380\u20131388.","DOI":"10.1016\/j.ophtha.2022.07.009"},{"issue":"4","key":"810_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","volume":"130","author":"NA Patel","year":"2023","unstructured":"Patel NA, Acaba-Berrocal LA, Hoyek S, Fan KC, Martinez-Castellanos MA, Baumal CR, et al. Comparison in retreatments between bevacizumab and Ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study. Ophthalmology. 2023;130(4):373\u20138.","journal-title":"Ophthalmology"},{"issue":"4","key":"810_CR18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.joco.2018.08.004","volume":"30","author":"R Roohipoor","year":"2018","unstructured":"Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Farahani AD, Khodabandeh A, Ebrahimi Adib N, et al. Intravitreal bevacizumab versus laser photocoagulation for treatment of type 1 retinopathy of prematurity in zone II. J Curr Ophthalmol. 2018;30(4):365\u20139.","journal-title":"J Curr Ophthalmol"},{"issue":"3","key":"810_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, et al. Comparing alternative Ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172(3):278\u201386.","journal-title":"JAMA Pediatr"},{"issue":"10208","key":"810_CR20","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551\u20139.","journal-title":"Lancet"},{"issue":"4","key":"810_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","volume":"328","author":"A Stahl","year":"2022","unstructured":"Stahl A, Sukgen EA, Wu W-C, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal Aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA. 2022;328(4):348\u201359. https:\/\/doi.org\/10.1001\/jama.2022.10564.","journal-title":"JAMA"},{"issue":"7","key":"810_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","volume":"106","author":"Z Wu","year":"2022","unstructured":"Wu Z, Zhao J, Lam W, Yang M, Chen L, Huang X, et al. Comparison of clinical outcomes of conbercept versus Ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol. 2022;106(7):975\u201379.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"810_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","volume":"118","author":"WC Wu","year":"2011","unstructured":"Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology. 2011;118(1):176\u201383.","journal-title":"Ophthalmology"},{"issue":"10","key":"810_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.clinthera.2024.08.011","volume":"46","author":"T Yang","year":"2024","unstructured":"Yang T, Zhang J, Hao Q, Ma S, Cheng X. Efficacy and safety of Aflibercept and Ranibizumab in the treatment of retinopathy of prematurity. Clin Ther. 2024;46(10):773\u20137.","journal-title":"Clin Ther"},{"issue":"2","key":"810_CR25","first-page":"CD009734","volume":"2","author":"MJ Sankar","year":"2016","unstructured":"Sankar MJ, Sankar J, Mehta M, Bhat V, Srinivasan R. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2016;2(2):CD009734.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"810_CR26","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008\u201315.","journal-title":"Ophthalmology"},{"issue":"6","key":"810_CR27","doi-asserted-by":"publisher","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","volume":"142","author":"WM Fierson","year":"2018","unstructured":"Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology. American association for pediatric ophthalmology and Strabismus, American association of certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142(6):e20183061.","journal-title":"Pediatrics"},{"issue":"2","key":"810_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125(2):218\u201326. PMID: 28867130.","journal-title":"Ophthalmology"},{"issue":"3","key":"810_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","volume":"42","author":"M Gunay","year":"2017","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of Bevacizumab, Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462\u20139. Epub 2016 Jul 15. PMID: 27420302.","journal-title":"Curr Eye Res"},{"issue":"7","key":"810_CR30","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","volume":"42","author":"EU Kabata\u015f","year":"2017","unstructured":"Kabata\u015f EU, Kurtul BE, Alt\u0131ayl\u0131k \u00d6zer P, Kabata\u015f N. Comparison of intravitreal Bevacizumab, intravitreal Ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017;42(7):1054\u20138.","journal-title":"Curr Eye Res"},{"issue":"2","key":"810_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","volume":"19","author":"M Isaac","year":"2015","unstructured":"Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS. 2015;19(2):140\u20134.","journal-title":"J AAPOS"},{"issue":"2","key":"810_CR32","first-page":"355","volume":"109","author":"N O\u2019Keeffe","year":"2016","unstructured":"O\u2019Keeffe N, Murphy J, O\u2019Keefe M, Lanigan B. Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: A 5 year follow up. Ir Med J. 2016;109(2):355. PMID: 27685689.","journal-title":"Ir Med J"},{"issue":"3","key":"810_CR33","first-page":"365","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C, B\u00fchrer C, Schunk KU, Girschick HJ, Winterhalter S. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101(3):365\u201370.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"810_CR34","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","volume":"39","author":"K Raghuram","year":"2019","unstructured":"Raghuram K, Isaac M, Yang J, Mireskandari K. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol. 2019;39(10):1300\u20138.","journal-title":"J Perinatol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00810-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:25:25Z","timestamp":1781630725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00810-9","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review involved data analysis from previously published studies and did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since this study did not involve recruiting participants or collecting new data, obtaining informed consent was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}